The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARVN | -65.46% | -56.48% | -15.32% | -43% |
| S&P | +16.23% | +94.45% | +14.22% | +131% |
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
The smaller biopharma outfit just inked an encouraging deal with an industry powerhouse.
Investors were hoping for better initial data from an early-stage trial of its prostate cancer therapy.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $22.40M | -70.7% |
| Gross Profit | $21.00M | -71.9% |
| Gross Margin | 93.75% | -4.0% |
| Market Cap | $537.22M | -70.5% |
| Market Cap / Employee | $1.25M | 0.0% |
| Employees | 430 | -3.4% |
| Net Income | -$61.20M | -73.9% |
| EBITDA | -$69.10M | -47.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $114.90M | -28.3% |
| Accounts Receivable | $0.50M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.10M | 800.0% |
| Short Term Debt | $2.00M | 42.9% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -27.37% | 0.0% |
| Return On Invested Capital | -36.59% | -0.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$96.60M | -294.8% |
| Operating Free Cash Flow | -$95.40M | -289.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.89 | 2.25 | 0.86 | 0.81 | -72.71% |
| Price to Sales | 32.04 | 41.51 | 20.51 | - | |
| Price to Tangible Book Value | 2.82 | 2.19 | 0.86 | 0.81 | -72.71% |
| Enterprise Value to EBITDA | -14.57 | -6.23 | -5.96 | 4.54 | -120.73% |
| Return on Equity | -60.0% | -63.3% | -60.8% | - | |
| Total Debt | $2.30M | $9.90M | $10.70M | $10.10M | 260.71% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
